Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / GH1



This biomarker is also known as:
  • IGHD1B,
  • hGH-N,
  • GH,
  • pituitary growth hormone,
  • Growth hormone,
  • GHN,
  • GH-N,
  • Growth hormone 1,
  • Somatotropin,
  • growth hormone 1,
  • Pituitary growth hormone,

View in BioMuta


Growth hormone, a secreted protein which exists as a monomer, dimer, trimer, tetramer and pentamer and is disulfide-linked or non-covalently associated in homopolymeric and heteropolymeric combinations, plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues. GH belongs to the somatotropin/prolactin family.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: GH1


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


GH1 alone was not a strong predictor of ovarian cancer.

Performance Comment

Of the ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. GH1 alone was not a strong predictor.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated publications found.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.